Preventing bleeds by treatment: new era for haemophilia changing the paradigm

Area of Science:

• Hematology
• Pediatric Hematology

Background:

• Severe hemophilia management has advanced with coagulation products, enabling near-normal lives for diagnosed patients.
• Early diagnosis and primary prophylaxis are key, but often delayed due to lack of family history, impacting timely treatment initiation.
• The delay between joint bleeding and arthropathy hinders the implementation of primary prophylaxis, highlighting the need for increased awareness and prompt diagnosis.

Purpose of the Study:

• To emphasize the importance of early diagnosis and primary prophylaxis in severe hemophilia management.
• To advocate for a reconsideration of episodic ('on demand') therapy as a primary treatment strategy.
• To highlight the need for data collection on current treatment regimens to optimize hemophilia care and guidelines.

Main Methods:

• Review of current treatment strategies and guidelines for severe hemophilia.
• Analysis of factors contributing to delayed diagnosis and treatment initiation.
• Emphasis on the importance of clinical presentation awareness and diagnostic prerequisites.

Main Results:

• Coagulation products enable normal lives, but only with early diagnosis and primary prophylaxis.
• Absence of family history frequently delays diagnosis and treatment initiation in severe hemophilia.
• Current guidelines necessitate a shift from episodic therapy towards proactive bleeding prevention strategies.

Conclusions:

• All severe hemophilia patients should receive a bleeding prevention strategy, given the availability of clotting factor concentrates and gene therapy.
• Optimizing care requires data collection on current treatment regimens to refine guidelines and improve patient outcomes.
• Proactive bleeding prevention is paramount for individuals with severe hemophilia.